Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what additional support his Department is providing to people living with asthma during the covid-19 outbreak.
Answered by Edward Argar - Minister of State (Ministry of Justice)
Through its communication to general practitioner practices and commissioners on 31 July 2020, NHS England and NHS Improvement asked general practice to restore activity to usual levels where clinically appropriate and reach out proactively to clinically vulnerable patients and those whose care may have been delayed.
The new Respiratory Clinical Networks bring together leaders from the National Health Service and other health and social care organisations, to transform the diagnosis, treatment and care for respiratory patients in their local area, focusing on reducing inequalities.
Public Health England continue to provide advice for people with long term health conditions during COVID-19.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data his Department holds on detection and diagnosis rates for atrial fibrillation in England (a) from January to May 2019 and (b) from January to May 2020 inclusive; and if he will make a statement.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The information is not available in the format requested. The Quality Outcomes Framework reports annually for atrial fibrillation and it is not possible to break down into monthly data.
A register of patients with atrial fibrillation is used to monitor cumulative recorded prevalence year-on-year. Recorded prevalence of atrial fibrillation increased from 1.98% in 2018/19 to 2.05% in 2019/20. Data for 2020/21 will be published during 2021.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people presented in hospital with ischemic stroke in (a) January, (b) February, (c) March and (d) April 2020.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The information is not held in the format requested. NHS Digital collects the number of finished admissions episodes which do not represent the number of patients, as a person may have more than one admission within the period.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether consultations of stakeholders conducted by the National Institute for Health and Care Excellence (NICE) may address policy and affordability issues, in the context of NICE's duty to promote innovation.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
Section 233 of the Health and Social Care Act 2012 provides that the National Institute of Health and Care Excellence (NICE) must have regard to the broad balance between benefits and costs and the desirability of promoting innovation. NICE is an independent organisation and is responsible for its consultation processes.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what additional support his Department is providing to people living with cystic fibrosis during the covid-19 outbreak.
Answered by Edward Argar - Minister of State (Ministry of Justice)
During the COVID-19 pandemic, NHS England and NHS Improvement have worked with the National Institute for Health and Care Excellence (NICE) and the cystic fibrosis (CF) clinical community to ensure additional guidance has been available to support care for patients with CF, both in hospital and away from hospital when appropriate. NICE published the ‘COVID-19 Rapid Guideline: Cystic Fibrosis’ in April 2020, which was updated in October 2020. This sets out guidance for clinicians and commissioners to maximise the safety of patients with CF and make the best use of National Health Service resources, while protecting staff from infection. The guidance is available at the following link:
www.nice.org.uk/guidance/ng170
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 July 2020 to Question 64351 on Pharmacy: Screening, what the terms of reference are for the evidence-based review of the NHS Health Check programme from Public Health England.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The Terms of Reference for the review of the NHS Health Check programme were published on 11 November 2020 and are available at the following link:
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to expand the use of digital technologies to improve the remote detection of atrial fibrillation as result of restrictions on face-to-face appointments during the covid-19 outbreak.
Answered by Nadine Dorries
The NHS is investing £9 million to fund a demonstrator project to test out new ways of providing treatment to people with Atrial Fibrillation using virtual clinics. NHSX continues to support and encourage emerging innovative diagnostic tools, for example through the Artificial Intelligence Health and Care Awards.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 July 2020 to Question 64355 on Health, what his Department's revised timeframe is for publishing the response to the consultation on Advancing our health: prevention in the 2020s.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The Prevention Green Paper, ‘Advancing our health: Prevention in the 2020s’ outlined commitments with varying timelines, regarding the services we receive, the choices we make and the conditions in which we live. The Government response to the consultation has been delayed due to the COVID-19 pandemic. Following the announcement of the National Institute for Health Protection in August, we are also considering the best future arrangements for the wide range of Public Health England’s non-health protection functions that are vital to support health improvement, prevention and delivery of health services and we will be setting out further details of our approach in due course.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 July 2020 to Question 64355 on Health, what his timeframe is for publishing the updated version of the 22 July 2019 Green Paper entitled, Advancing our health: prevention in the 2020s.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The Prevention Green Paper, ‘Advancing our health: Prevention in the 2020s’ outlined commitments with varying timelines, regarding the services we receive, the choices we make and the conditions in which we live. The Government response to the consultation has been delayed due to the COVID-19 pandemic. Following the announcement of the National Institute for Health Protection in August, we are also considering the best future arrangements for the wide range of Public Health England’s non-health protection functions that are vital to support health improvement, prevention and delivery of health services and we will be setting out further details of our approach in due course.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department is working on an agreement with Synairgen plc to supply inhaled treatment for covid-19.
Answered by Jo Churchill - Minister of State (Department for Work and Pensions)
The Department with the National Institute for Health Research (NIHR) has established a single United Kingdom-wide process which labels COVID-19 research with the most potential with Urgent Public Health (UPH) status. Any trials evaluating the effectiveness of inhaled treatments are subject to this same process.
National and international trials are monitored by the RAPID-C19 initiative, which aims to get treatments for COVID-19 to National Health Service patients quickly and safely. This process begins with scanning all trials for COVID-19 treatments. Any promising drugs will be identified for further review.
Synairgen have been requested to submit a formal submission to UK-CTAP and NIHR UPH for review, where the inhaled interferon beta-1, SGN001 will be reviewed by a panel of independent experts to assess if it will be suitable to be incorporated into the RECOVERY+ trial or an independent trial, for Phase III.
UK-CTAP is an independent COVID-19 Therapeutics Advisory Panel, which will advise on what treatments should be proposed for testing through RECOVERY+. As with all other therapeutic compounds in trial, progress of the effectiveness will continue to be monitored by the Chief Medical Officer, NIHR UPH and RAPID C-19.